Clinical Trial Update: JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating JMT101 in combination with mitoxantrone liposome for recurrent or metastatic nasopharyngeal cancer and is not yet recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Cancer

Drugs mentioned

• JMT101
• Mitoxantrone Liposome (mitoxantrone liposome)

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy | Phase 2 | Status: NOT_YET_RECRUITING